CVS Health (NYSE:CVS - Get Free Report) had its price target upped by equities research analysts at Piper Sandler from $72.00 to $74.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "overweight" rating on the pharmacy operator's stock. Piper Sandler's price target would indicate a potential upside of 8.27% from the company's previous close.
Several other brokerages have also issued reports on CVS. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 target price on the stock in a research report on Tuesday, December 3rd. TD Cowen boosted their price objective on CVS Health from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Monday, November 25th. Evercore ISI lifted their price target on CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Monday, January 27th. Truist Financial increased their price objective on CVS Health from $60.00 to $76.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, Barclays upped their target price on shares of CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $70.39.
Check Out Our Latest Stock Analysis on CVS
CVS Health Price Performance
Shares of CVS stock traded up $1.30 during mid-day trading on Friday, hitting $68.35. 3,027,637 shares of the stock were exchanged, compared to its average volume of 11,068,675. CVS Health has a 52-week low of $43.56 and a 52-week high of $80.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a market cap of $86.18 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. The firm has a fifty day moving average of $60.60 and a 200 day moving average of $57.35.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Research analysts anticipate that CVS Health will post 5.89 earnings per share for the current year.
Insider Activity
In other CVS Health news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael F. Mahoney acquired 30,000 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.24% of the company's stock.
Institutional Investors Weigh In On CVS Health
Several large investors have recently bought and sold shares of CVS. Legacy Investment Solutions LLC acquired a new stake in CVS Health in the third quarter valued at approximately $31,000. Ridgewood Investments LLC raised its holdings in shares of CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 450 shares in the last quarter. Stonebridge Financial Group LLC purchased a new stake in shares of CVS Health during the 4th quarter worth $28,000. RPg Family Wealth Advisory LLC acquired a new position in shares of CVS Health during the third quarter worth $40,000. Finally, Hopwood Financial Services Inc. purchased a new position in CVS Health in the fourth quarter valued at $29,000. Hedge funds and other institutional investors own 80.66% of the company's stock.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Read More
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
